Document is current
Any future updates will be listed below
-
Authors
Fung, Hoki
Potash, Ruby M.
Krystal, Andrew https://orcid.org/0000-0002-6702-781X
Pizzagalli, Diego A. https://orcid.org/0000-0002-7772-1143
Sacchet, Matthew D.
-
Funding
Funding for this research was provided by:
Rappaport Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH125850)
Brain and Behavior Research Foundation (28972)
The Ride for Mental Health Gatto Foundation
- License Information
-
More Information
Article History
Received: 24 March 2025
Revised: 16 April 2025
Accepted: 1 May 2025
First Online: 13 May 2025
Competing interests
: Over the past 3 years, DAP has received consulting fees from Boehringer Ingelheim, Compass Pathways, Engrail Therapeutics, Karla Therapeutics, Neumora Therapeutics, Neurocrine Biosciences, Neuroscience Software, Otsuka, Sage Therapeutics, Sama Therapeutics, Sunovion Therapeutics, and Takeda; he has received honoraria from the American Psychological Association, Psychonomic Society and Springer (for editorial work) as well as Alkermes; he has received research funding from the Brain and Behavior Research Foundation, Dana Foundation, Wellcome Leap, Millennium Pharmaceuticals, and NIMH; he has received stock options from Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. All other authors have no conflicts of interest or relevant disclosures.
